Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2010
12/29/2010CN101036774B Quality control method of compound cantharidin oral preparations
12/29/2010CA2803330A1 Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
12/29/2010CA2766618A1 Polymorphic form d of bazedoxifene acetate and methods of preparing same
12/29/2010CA2766322A1 Methods of using corticotropin-releasing factor for the treatment of cancer
12/29/2010CA2766320A1 Acid-labile trigger units
12/29/2010CA2766272A1 Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
12/29/2010CA2766193A1 Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators
12/29/2010CA2766151A1 Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
12/29/2010CA2766106A1 Use of derivatives of indoles for the treatment of cancer
12/29/2010CA2765997A1 Treatment of endometriosis
12/29/2010CA2765988A1 Novel compound useful for the treatment of degenerative and inflammatory diseases
12/29/2010CA2765983A1 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
12/29/2010CA2765678A1 Substituted hydroxamic acids and uses thereof
12/29/2010CA2764526A1 The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
12/29/2010CA2763766A1 3-substituted-8-substituted-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
12/28/2010USRE42014 Pharmaceutical compositions
12/28/2010US7858824 Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them
12/28/2010US7858789 Affinity for somatostatin receptors; used for the treatment of acromegalia, hypophyseal adenomas or endocrine gastroenteropancreatic tumors including carcinoid syndrome; 4-(urea or thiourea substituted)-1-alkylpiperidines
12/28/2010US7858785 1-(2-{5-Chloro-4-[5-(4-fluoro-phenylimino)-4-methyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl]-pyrimidin-2-ylamino}-ethyl)-5,5-dimethyl-imidazolidine, useful for treating diseases mediated by polo-like kinase 1, such as rheumatoid arthritis and breast cancer; antiproliferative agents
12/28/2010US7858782 e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders
12/28/2010US7858765 OX40R binding agents
12/28/2010US7858746 recognize selectively both Programmed Death 1 (PD-1) protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1; for medical treatment and/or prevention of diseases caused by immune abnormality
12/28/2010US7858659 Redox therapy for tumors
12/28/2010US7858626 Pyrimidineamines as angiogenesis modulators
12/28/2010US7858616 treating excessive or abnormal endothelial cell proliferation comprising administering compounds such as 3-Z-[1-(4-dimethylaminomethylanilino)-1-(3-(2-carboxyethyl)phenyl)methylene]-6-chloro-2-indolinone; antitumor, anticarcinogenic or antiproliferative agents
12/28/2010US7858577 Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2
12/28/2010US7858091 Insulin-like growth factor binding protein specific monoclonal antibody for use in diagnosis, prevention and treatment of cell proliferative, inflammatory, autoimmune, muscular and vision disorders
12/28/2010US7858088 chimeric anti-EGP-2-binding scFv fragment 4D5MOC-A; for treatment of human carcinomas; Pseudomonas exotoxin A
12/23/2010WO2010148390A2 Polyamine transport inhibitors as novel therapeutics
12/23/2010WO2010148223A2 Anti-vegf antibodies and their uses
12/23/2010WO2010148138A2 Camptothecin derivatives
12/23/2010WO2010148042A1 Oxabicyclo [4.1.o]hept-b-en-s-ylcarbamoyl derivatives inhibiting the nuclear factor-kappa(b) - (nf-kb)
12/23/2010WO2010148007A2 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
12/23/2010WO2010147971A2 Il23 modified viral vector for recombinant vaccines and tumor treatment
12/23/2010WO2010147917A1 Disubstituted phthalazine hedgehog pathway antagonists
12/23/2010WO2010147666A1 Compounds useful as carbonic anhydrase modulators and uses thereof
12/23/2010WO2010147274A1 Secretory granules and granulogenic factors as a target for cancer treatment
12/23/2010WO2010147234A1 Diarylamide-spirodiamine derivative
12/23/2010WO2010147138A1 Gene encoding fatty acid elongase, and use thereof
12/23/2010WO2010147094A1 Compound having spiro-bonded cyclic group and use thereof
12/23/2010WO2010146634A1 Immunotherapeutic agent and immunotherapy for pancreatic cancer
12/23/2010WO2010146622A1 Nfat signal inhibitor and calcineurin inhibitor
12/23/2010WO2010146351A1 Indolylmethyl-morpholine derivatives as kinase inhibitors
12/23/2010WO2010146299A1 Azetidine-derived esters, preparation thereof, and therapeutic use thereof as cannabinoid receptor modulators
12/23/2010WO2010146236A1 Urea substituted sulphonamide derivatives
12/23/2010WO2010146113A1 Antifungal 1, 2, 4-triazolyl derivatives having a 5- sulfur substituent
12/23/2010WO2010146112A1 Antifungal 1, 2, 4-triazolyl derivatives
12/23/2010WO2010146111A1 Antifungal 1, 2, 4-triazolyl derivatives
12/23/2010WO2010146104A1 Thiadiazole derivatives and their use for the treatment of disorders mediated by slpl receptors
12/23/2010WO2010145998A1 Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
12/23/2010WO2010145903A1 New therapeutical uses of inecalcitol
12/23/2010WO2010145895A1 Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
12/23/2010WO2010145376A1 Tripeptide boronic acid or boronic ester, preparative method and use thereof
12/23/2010WO2010145197A1 Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors
12/23/2010WO2010145192A1 Mangiferin-berberine salt, manufacturing method and use thereof
12/23/2010WO2010145035A1 Renal cell carcinoma biomarkers
12/23/2010WO2010144946A1 Method of determining response to treatment with immunomodulatory composition
12/23/2010WO2010122275A8 Pharmaceutical preparation
12/23/2010WO2010115629A3 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
12/23/2010WO2010095042A3 Pyridocarbazole type compounds and applications thereof
12/23/2010WO2010094981A3 Antibody therapy
12/23/2010WO2010093450A3 Pten phosphorylation-driven restistance to cancer treatment and altered prognosis
12/23/2010WO2010072770A3 Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
12/23/2010WO2010023195A3 Compositions and methods for treating cancer
12/23/2010WO2010009124A3 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
12/23/2010WO2009097394A3 Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
12/23/2010US20100325744 Non-glycosylated recombinant monovalent antibodies
12/23/2010US20100325743 Marks as modifiers of the p53 pathway and methods of use
12/23/2010US20100324288 Dihydropteridinone Compounds
12/23/2010US20100324147 Arylcyclopropylamines and methods of use
12/23/2010US20100324143 Bis(thio-hydrazide amide) salts for treatment of cancers
12/23/2010US20100324133 Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders
12/23/2010US20100324130 Daa peripheral benzodiazepine receptor ligand for cancer imaging and treatment
12/23/2010US20100324128 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof
12/23/2010US20100324126 Syn3 compositions and methods
12/23/2010US20100324122 Modulation of sglt2 expression
12/23/2010US20100324119 Reducing irf4, dusp22, or flj43663 polypeptide expression
12/23/2010US20100324118 Method for the Promotion of Angiogenesis, Vascularization, or Vascular Repair or for the Inhibition of Tumor Angiogenesis
12/23/2010US20100324116 Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells
12/23/2010US20100324115 Treatment of Squamous Cell Carcinoma with HSP27 Antisense Oligonucleotides and Radiotherapy
12/23/2010US20100324113 Delivery Method
12/23/2010US20100324112 Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
12/23/2010US20100324108 Substituted isoindoline-1,3-dione derivatives
12/23/2010US20100324106 Compounds
12/23/2010US20100324105 Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids
12/23/2010US20100324094 Conformationally Restrained Epothilone Analogues as Anti-Leukemic Agents
12/23/2010US20100324092 Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
12/23/2010US20100324089 Anti-inflammatory composition
12/23/2010US20100324087 Combined use of angiogenesis inhibitor and taxane
12/23/2010US20100324086 Compounds and methods
12/23/2010US20100324083 Combinations of Organic Compounds
12/23/2010US20100324074 Protein Kinase Inhibitors
12/23/2010US20100324071 Novel glucokinase activators and methods of using same
12/23/2010US20100324066 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
12/23/2010US20100324063 Jak2 tyrosine kinase inhibition
12/23/2010US20100324062 Compounds and compositions as protein kinase inhibitors
12/23/2010US20100324061 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
12/23/2010US20100324056 Biphenyl and phenyl-pyridine amides as p2x3 and p2x2/3 antagonists
12/23/2010US20100324050 Inhibitors of bruton's tyrosine kinase
12/23/2010US20100324048 Disubstituted phthalazine hedgehog pathway antagonists
1 ... 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 ... 2211